Takeda Academic Innovation

Cathy Tralau-Stewart PhD FRSC
Senior Director Alliances
Center for External Innovation
Takeda

TAKEDA HAS A DIFFERENTIATED R&D ENGINE

A Diverse and Dynamic Pipeline[1]

200+
ACTIVE PARTNERSHIPS

40
NEW MOLECULAR ENTITY CLINICAL STAGE ASSETS[2]

RESEARCH PROGRAMS



PIPELINE WITH ORPHAN DRUG DESIGNATION

Expanding Critical Capabilities

- CELL THERAPY
- GENE THERAPY
- DATA SCIENCES

1 Pipeline as of July 31, 2019
2 Includes assets in our four focus Therapeutic Areas and targeted R&D investments in Plasma-Derived Therapies and Vaccines

TAKEDA ACADEMIC INNOVATION

Combining the best of academic and industry research to identify bold projects with potential for breakthrough therapies and to accelerate development



9 Alliances
19 Institutes
Pan-TA
Cross-Modality

TAKEDA AREAS OF INTEREST

EARLY INNOVATION & PLATFORMS	RARE DISEASES	ONCOLOGY	GASTROENTEROLOGY	NEUROSCIENCE
Gene and Cell Therapy Technologies	Lysosomal Storage Disorders	I/O Cell Engagers & Cell Therapy	IBD inflammation	Nervous system protection/repair
Antibodies, Biologics, Small Molecules	Rare Hematology	I/O Cold to Hot	Motility disorders	Precision medicine approach
Small Molecule-RNA binding	Inborn Metabolic Disorders	Tumor microenvironment Immune cells: B, NK, and T eff cells, macrophages	Liver disorders (especially F3, F4 NASH)	BBB shuttle/delivery
Delivery technologies (LNPs, Exosomes, etc.)	Musculoskeletal, Neuromuscular	Target ID (MM, MSS-CRC, TNBC, Pancreatic, AML, lymphoma)	Microbiome	Synergistic Pharmacology (Polypharmacology)
Protein Degradation	Complement-mediated	Patient sample access	Genetic linked diseases	Neuromuscular
Translational Medicine	Platforms: delivery, cell/gene therapy, immune tolerance	Delivery, Armoring Payloads	Cell Therapy	Genetic linked diseases
AI applied to patient and clinical data, Data Science, RWE		Translational models	Drug Delivery	Any other emerging therapeutic approaches

ONE – PROJECT TEAM COLLABORATIVE RELATIONSHIP BUILDING

- Takeda's aim is to build relationships which enable the **combination of academic and industrial skills and knowledge** to accelerate the development of life changing therapeutics to patients
- Flexible use of in-kind in-house, CRO and funding-based **resources** to accelerate the project plan
- Regular in–person and webex meetings
- Direct support of academic research to deliver pre-clinical and clinical Proof of Concept studies
- Flexible agreements ranging from SRAs to broad alliance and consortium agreements recognizing each partner's skills and needs
- Support for a range of exits including licenses, incubation & start-up creation

CONTACT

Cathy Tralau-Stewart PhD FRSC

Catherine.Tralau-Stewart@Takeda.com